Gastroscopes Market by Product (Flexible, Rigid), Distribution Channel (Offline, Online), End User, Application - Global Forecast 2025-2032
Description
The Gastroscopes Market was valued at USD 2.96 billion in 2024 and is projected to grow to USD 3.17 billion in 2025, with a CAGR of 7.32%, reaching USD 5.21 billion by 2032.
Concise orientation to the current gastroscope landscape emphasizing clinical imperatives, technology convergence, and supply chain realities
The gastroscope sector sits at the intersection of precision engineering, clinical demand for minimally invasive procedures, and accelerating technological innovation. Recent advances in imaging, miniaturization, and single-use instrumentation have reshaped clinician preferences and procurement criteria, while growing emphasis on infection control and procedural efficiency has driven renewed interest in device lifecycle management.
This introduction frames the current industry environment by highlighting the convergence of clinical imperatives and supply chain realities. It synthesizes how imaging performance, sterilization workflows, and device ergonomics increasingly determine adoption curves. Moreover, it underscores that regulatory scrutiny and reimbursement dynamics remain central forces influencing product design and market access strategies.
By orienting readers to these structural drivers, the introduction sets expectations for the subsequent analysis and recommendations. It also clarifies the scope of the study: a focus on device categories, end-user settings, clinical applications, distribution channels, and regional dynamics that collectively shape competitive positioning and operational priorities for manufacturers and healthcare purchasers.
Analysis of how digital imaging, sterilization demands, and evolving procurement models are reshaping competitive and clinical priorities in gastroscope markets
The gastroscope landscape has undergone a series of transformative shifts that are redefining value propositions and competitive dynamics. Technological progress in video chip sensors, light sources, and disposable materials has broadened the performance envelope of flexible instruments, while parallel advances in sterilization technologies and reprocessing standards have materially influenced the calculus between reusable and single-use devices.
Concurrently, procurement behaviors have shifted as health systems prioritize infection prevention and predictable operating costs, prompting renewed evaluation of device total cost of ownership and service models. The emergence of hybrid purchasing arrangements, including device-as-a-service and bundled procedural offerings, has encouraged manufacturers to develop integrated solutions that extend beyond the instrument itself into consumables, training, and remote diagnostics.
Regulatory emphasis on device traceability and post-market surveillance has also intensified, creating incentives for vendors to invest in digital instrumentation and data platforms that enable real-world performance monitoring. Taken together, these shifts favor manufacturers that can marry clinical-grade optics and ergonomics with robust service capabilities, regulatory compliance, and adaptable commercial models.
Examination of how recent tariff measures and trade policy shifts are prompting supply chain reconfiguration and commercial adaptation for device manufacturers
Recent U.S. tariff actions and trade policy initiatives announced for 2025 have introduced a new layer of operational complexity for gastroscope manufacturers and their global supply chains. Tariff adjustments can raise landed costs for imported components and finished devices, prompting firms to reassess sourcing strategies, supplier contracts, and manufacturing footprints to protect margin and maintain price competitiveness.
In response to these trade measures, many companies are exploring mitigation strategies such as nearshoring critical production steps, diversifying supplier bases across tariff-exempt jurisdictions, and redesigning assemblies to incorporate locally sourced subcomponents where feasible. These adjustments are often accompanied by increased emphasis on supply chain transparency and scenario planning so that procurement teams can quantify exposure and prioritize resilience-enhancing investments.
Moreover, tariffs influence commercial negotiations with customers who increasingly demand clarity on cost drivers and predictability of supply. As a result, manufacturers are refining their contracting language, adopting more frequent price review mechanisms, and accelerating conversations around value-based purchasing arrangements that distribute cost volatility. Overall, the tariff environment has catalyzed structural reassessment of global operations and reinforced the strategic importance of flexible production networks and supplier relationships.
Insightful segmentation synthesis linking product architectures, clinical settings, applications, and distribution pathways to clarify adoption drivers and competitive focus areas
Segmentation analysis reveals differentiated dynamics across product types, end-user settings, clinical applications, and distribution pathways that collectively shape competitive advantage. Product-level distinctions between flexible and rigid gastroscopes drive divergent development priorities: flexible systems emphasize imaging fidelity, channel functionality, and maneuverability, while rigid instruments concentrate on structural robustness and single-use convenience. Within the flexible category, the fiberoptic approach continues to serve legacy niches where cost and simplicity matter, whereas video-based flexible systems command attention for superior visualization and digital integration. Rigid instruments bifurcate into reusable models that prioritize durability and lifecycle service, and single-use variants that address infection-control imperatives and alleviate reprocessing burdens.
End-user segmentation further refines adoption patterns across ambulatory surgical centers, clinics, and hospitals, each demanding specific configurations of capital intensity, throughput optimization, and on-site support. Ambulatory surgical centers often seek compact, fast-turnaround platforms that maximize procedural efficiency, clinics favor cost-effective diagnostic solutions with straightforward workflows, and hospitals require scalable instrumentation compatible with multi-specialty suites and complex therapeutic interventions.
Application-focused segmentation highlights the differing technical and service requirements for combined procedural platforms versus dedicated diagnostic or therapeutic instruments. Combined systems must balance diagnostic acuity with therapeutic channel robustness, whereas diagnostic-focused tools prioritize imaging performance and ergonomics, and therapeutic devices emphasize accessory compatibility and operational force control. Distribution channel segmentation shows that direct sales relationships enable deep clinical collaboration and customized service agreements, distributors provide breadth of reach and channel-specific support, and online channels create opportunities for rapid replenishment and standardized offerings. Together these segmentation lenses guide product development priorities, go-to-market strategies, and post-sales service investments.
Comparative regional analysis highlighting how regulatory regimes, reimbursement priorities, and manufacturing footprints shape demand and commercialization strategies
Regional dynamics exert a powerful influence on regulatory burdens, reimbursement frameworks, clinical practice patterns, and supply chain topology across the Americas, Europe Middle East & Africa, and Asia-Pacific markets. In the Americas, robust capital investments and an emphasis on infection prevention are driving interest in advanced visualization and single-use options in both outpatient and inpatient settings. The regulatory framework in many jurisdictions within the region incentivizes documented sterilization and device traceability, making digital integration and robust post-market data capabilities important differentiators.
Across Europe Middle East & Africa, fragmented reimbursement landscapes and diverse regulatory regimes require manufacturers to adopt localized market entry strategies and tailored clinical evidence generation. Many health systems in this region emphasize cost containment and value demonstration, which increases the importance of lifecycle support, reprocessing efficiency, and demonstrable clinical outcomes. In addition, emerging markets within the region present growth opportunities contingent on channel partner strength and localized training programs.
Asia-Pacific exhibits varied maturity levels: advanced markets are rapidly adopting video-flexible systems and digitally enabled platforms, while other countries prioritize scalable, cost-effective solutions that match constrained capital budgets. Regional manufacturing capacity in Asia-Pacific also plays a role, with localized production influencing lead times and cost structures. Collectively, these regional insights underscore the need for flexible market entry approaches, nuanced value propositions, and differentiated support models to address the distinct priorities of providers in each geography.
Strategic company-level analysis revealing how integrated service models, digital partnerships, and manufacturing agility determine competitive standing in endoscopy
Competitive intensity in the gastroscope space is shaped by a mix of incumbent medical device manufacturers, specialist endoscopy innovators, and newer entrants pursuing single-use or digitally native platforms. Companies that have invested in integrated clinical support models, robust field service networks, and evidence-generation capabilities tend to maintain stronger ties with hospital procurement teams, enabling collaborative pilots and broader product adoption. Strategic partnerships between device producers and imaging or software firms are also increasingly common as vendors seek to embed data capture and analytics into clinical workflows.
Innovation pathways split between incremental improvements in optics, articulation, and ergonomics and more disruptive approaches centered on disposable instrumentation, cloud-enabled performance monitoring, and remote training capabilities. Supply chain stewardship and quality assurance remain cornerstones of competitive advantage, particularly when regulatory scrutiny and procurement requirements demand consistent traceability and documented sterilization performance. In this environment, capital allocation decisions that prioritize manufacturing flexibility, clinical evidence generation, and aftermarket service competencies are critical for sustaining differentiated positioning.
Taken together, these company-level dynamics favor organizations that can operationalize cross-functional collaboration between R&D, regulatory, and commercial teams while maintaining the agility to adapt product offerings and business models to shifting clinical and policy environments.
Actionable recommendations urging modular design, supply chain resilience, and service-led commercial models to capture clinical preference shifts and mitigate risk
Industry leaders should adopt a set of focused, high-impact actions to capitalize on evolving clinical needs and policy pressures while mitigating operational risk. First, prioritize modular product architectures that enable rapid adaptation across flexible and rigid platforms, ensuring that core optics and electronic subsystems can be upgraded without full instrument redesign. This approach reduces time-to-market for incremental improvements and supports tailored offerings for different end-user environments.
Second, invest in supply chain resilience through geographic diversification of critical component sourcing, strategic partnerships with key suppliers, and enhanced inventory visibility. Scenario planning for tariff and trade volatility should be integrated into procurement governance so that pricing and contracting strategies can be executed with clarity. Third, scale post-sales services and data capabilities to offer bundled solutions that combine instrumentation with training, remote diagnostics, and performance analytics, thereby strengthening customer lock-in and enabling evidence-based value conversations with payers and health systems.
Finally, adopt commercial flexibility by offering multiple purchasing and financing options, including managed services or subscription models, to align with varying capital constraints across ambulatory centers, clinics, and hospitals. Implementing these recommendations will position organizations to capture clinical preference shifts, reduce exposure to supply disruptions, and build durable customer relationships.
Description of the mixed-method research approach integrating clinician interviews, supplier assessments, regulatory review, and scenario analysis to ensure robust insights
The research methodology underlying this analysis integrates qualitative and quantitative evidence streams to ensure a robust, triangulated perspective on industry dynamics. Primary inputs include structured interviews with clinicians, procurement leaders, and device engineering experts, which provide frontline insight into procedural preferences, reprocessing realities, and clinical workflow constraints. These interviews are complemented by supplier engagements and technical assessments that clarify manufacturing capabilities and component-level dependencies.
Secondary research encompasses regulatory guidance documents, clinical guidelines, and peer-reviewed literature on endoscopic performance and infection control. Technical validation was performed through cross-referencing product literature, device specifications, and reported outcomes from clinical studies to ensure consistency across claims and observed practice. The analytical framework emphasizes sensitivity testing and scenario analysis to explore how supply chain shocks, regulatory changes, and clinical adoption patterns could influence operational choices.
Throughout the research process, care was taken to maintain objectivity, document sources, and apply consistent criteria for evaluating evidence quality. This methodology supports actionable insights while acknowledging the complexity and regional heterogeneity that characterize the global gastroscope ecosystem.
Synthesis of strategic implications showing why integrating technical excellence with service capabilities and supply chain resilience is essential for future success
The conclusion synthesizes the principal implications for stakeholders operating in the gastroscope domain: technological innovation, procurement shifts, and trade policy considerations are collectively driving a period of strategic realignment. Manufacturers that successfully integrate high-performance imaging, service-centric commercial models, and adaptable manufacturing footprints will be better positioned to respond to evolving clinical priorities and regulatory expectations.
Moreover, the interplay between reusable and single-use paradigms, varied end-user requirements across ambulatory centers, clinics, and hospitals, and region-specific regulatory and reimbursement landscapes underscores the imperative of differentiated product and market strategies. Organizations should therefore pursue targeted investments in clinical evidence generation, post-market surveillance, and supply chain transparency to preserve customer trust and protect operational continuity.
In sum, the industry is moving toward solutions that blend clinical excellence with pragmatic service and supply capabilities. Stakeholders who act decisively to align product roadmaps, commercial structures, and operational resilience will capture disproportionate value as providers recalibrate priorities in response to both clinical needs and external policy pressures.
Note: PDF & Excel + Online Access - 1 Year
Concise orientation to the current gastroscope landscape emphasizing clinical imperatives, technology convergence, and supply chain realities
The gastroscope sector sits at the intersection of precision engineering, clinical demand for minimally invasive procedures, and accelerating technological innovation. Recent advances in imaging, miniaturization, and single-use instrumentation have reshaped clinician preferences and procurement criteria, while growing emphasis on infection control and procedural efficiency has driven renewed interest in device lifecycle management.
This introduction frames the current industry environment by highlighting the convergence of clinical imperatives and supply chain realities. It synthesizes how imaging performance, sterilization workflows, and device ergonomics increasingly determine adoption curves. Moreover, it underscores that regulatory scrutiny and reimbursement dynamics remain central forces influencing product design and market access strategies.
By orienting readers to these structural drivers, the introduction sets expectations for the subsequent analysis and recommendations. It also clarifies the scope of the study: a focus on device categories, end-user settings, clinical applications, distribution channels, and regional dynamics that collectively shape competitive positioning and operational priorities for manufacturers and healthcare purchasers.
Analysis of how digital imaging, sterilization demands, and evolving procurement models are reshaping competitive and clinical priorities in gastroscope markets
The gastroscope landscape has undergone a series of transformative shifts that are redefining value propositions and competitive dynamics. Technological progress in video chip sensors, light sources, and disposable materials has broadened the performance envelope of flexible instruments, while parallel advances in sterilization technologies and reprocessing standards have materially influenced the calculus between reusable and single-use devices.
Concurrently, procurement behaviors have shifted as health systems prioritize infection prevention and predictable operating costs, prompting renewed evaluation of device total cost of ownership and service models. The emergence of hybrid purchasing arrangements, including device-as-a-service and bundled procedural offerings, has encouraged manufacturers to develop integrated solutions that extend beyond the instrument itself into consumables, training, and remote diagnostics.
Regulatory emphasis on device traceability and post-market surveillance has also intensified, creating incentives for vendors to invest in digital instrumentation and data platforms that enable real-world performance monitoring. Taken together, these shifts favor manufacturers that can marry clinical-grade optics and ergonomics with robust service capabilities, regulatory compliance, and adaptable commercial models.
Examination of how recent tariff measures and trade policy shifts are prompting supply chain reconfiguration and commercial adaptation for device manufacturers
Recent U.S. tariff actions and trade policy initiatives announced for 2025 have introduced a new layer of operational complexity for gastroscope manufacturers and their global supply chains. Tariff adjustments can raise landed costs for imported components and finished devices, prompting firms to reassess sourcing strategies, supplier contracts, and manufacturing footprints to protect margin and maintain price competitiveness.
In response to these trade measures, many companies are exploring mitigation strategies such as nearshoring critical production steps, diversifying supplier bases across tariff-exempt jurisdictions, and redesigning assemblies to incorporate locally sourced subcomponents where feasible. These adjustments are often accompanied by increased emphasis on supply chain transparency and scenario planning so that procurement teams can quantify exposure and prioritize resilience-enhancing investments.
Moreover, tariffs influence commercial negotiations with customers who increasingly demand clarity on cost drivers and predictability of supply. As a result, manufacturers are refining their contracting language, adopting more frequent price review mechanisms, and accelerating conversations around value-based purchasing arrangements that distribute cost volatility. Overall, the tariff environment has catalyzed structural reassessment of global operations and reinforced the strategic importance of flexible production networks and supplier relationships.
Insightful segmentation synthesis linking product architectures, clinical settings, applications, and distribution pathways to clarify adoption drivers and competitive focus areas
Segmentation analysis reveals differentiated dynamics across product types, end-user settings, clinical applications, and distribution pathways that collectively shape competitive advantage. Product-level distinctions between flexible and rigid gastroscopes drive divergent development priorities: flexible systems emphasize imaging fidelity, channel functionality, and maneuverability, while rigid instruments concentrate on structural robustness and single-use convenience. Within the flexible category, the fiberoptic approach continues to serve legacy niches where cost and simplicity matter, whereas video-based flexible systems command attention for superior visualization and digital integration. Rigid instruments bifurcate into reusable models that prioritize durability and lifecycle service, and single-use variants that address infection-control imperatives and alleviate reprocessing burdens.
End-user segmentation further refines adoption patterns across ambulatory surgical centers, clinics, and hospitals, each demanding specific configurations of capital intensity, throughput optimization, and on-site support. Ambulatory surgical centers often seek compact, fast-turnaround platforms that maximize procedural efficiency, clinics favor cost-effective diagnostic solutions with straightforward workflows, and hospitals require scalable instrumentation compatible with multi-specialty suites and complex therapeutic interventions.
Application-focused segmentation highlights the differing technical and service requirements for combined procedural platforms versus dedicated diagnostic or therapeutic instruments. Combined systems must balance diagnostic acuity with therapeutic channel robustness, whereas diagnostic-focused tools prioritize imaging performance and ergonomics, and therapeutic devices emphasize accessory compatibility and operational force control. Distribution channel segmentation shows that direct sales relationships enable deep clinical collaboration and customized service agreements, distributors provide breadth of reach and channel-specific support, and online channels create opportunities for rapid replenishment and standardized offerings. Together these segmentation lenses guide product development priorities, go-to-market strategies, and post-sales service investments.
Comparative regional analysis highlighting how regulatory regimes, reimbursement priorities, and manufacturing footprints shape demand and commercialization strategies
Regional dynamics exert a powerful influence on regulatory burdens, reimbursement frameworks, clinical practice patterns, and supply chain topology across the Americas, Europe Middle East & Africa, and Asia-Pacific markets. In the Americas, robust capital investments and an emphasis on infection prevention are driving interest in advanced visualization and single-use options in both outpatient and inpatient settings. The regulatory framework in many jurisdictions within the region incentivizes documented sterilization and device traceability, making digital integration and robust post-market data capabilities important differentiators.
Across Europe Middle East & Africa, fragmented reimbursement landscapes and diverse regulatory regimes require manufacturers to adopt localized market entry strategies and tailored clinical evidence generation. Many health systems in this region emphasize cost containment and value demonstration, which increases the importance of lifecycle support, reprocessing efficiency, and demonstrable clinical outcomes. In addition, emerging markets within the region present growth opportunities contingent on channel partner strength and localized training programs.
Asia-Pacific exhibits varied maturity levels: advanced markets are rapidly adopting video-flexible systems and digitally enabled platforms, while other countries prioritize scalable, cost-effective solutions that match constrained capital budgets. Regional manufacturing capacity in Asia-Pacific also plays a role, with localized production influencing lead times and cost structures. Collectively, these regional insights underscore the need for flexible market entry approaches, nuanced value propositions, and differentiated support models to address the distinct priorities of providers in each geography.
Strategic company-level analysis revealing how integrated service models, digital partnerships, and manufacturing agility determine competitive standing in endoscopy
Competitive intensity in the gastroscope space is shaped by a mix of incumbent medical device manufacturers, specialist endoscopy innovators, and newer entrants pursuing single-use or digitally native platforms. Companies that have invested in integrated clinical support models, robust field service networks, and evidence-generation capabilities tend to maintain stronger ties with hospital procurement teams, enabling collaborative pilots and broader product adoption. Strategic partnerships between device producers and imaging or software firms are also increasingly common as vendors seek to embed data capture and analytics into clinical workflows.
Innovation pathways split between incremental improvements in optics, articulation, and ergonomics and more disruptive approaches centered on disposable instrumentation, cloud-enabled performance monitoring, and remote training capabilities. Supply chain stewardship and quality assurance remain cornerstones of competitive advantage, particularly when regulatory scrutiny and procurement requirements demand consistent traceability and documented sterilization performance. In this environment, capital allocation decisions that prioritize manufacturing flexibility, clinical evidence generation, and aftermarket service competencies are critical for sustaining differentiated positioning.
Taken together, these company-level dynamics favor organizations that can operationalize cross-functional collaboration between R&D, regulatory, and commercial teams while maintaining the agility to adapt product offerings and business models to shifting clinical and policy environments.
Actionable recommendations urging modular design, supply chain resilience, and service-led commercial models to capture clinical preference shifts and mitigate risk
Industry leaders should adopt a set of focused, high-impact actions to capitalize on evolving clinical needs and policy pressures while mitigating operational risk. First, prioritize modular product architectures that enable rapid adaptation across flexible and rigid platforms, ensuring that core optics and electronic subsystems can be upgraded without full instrument redesign. This approach reduces time-to-market for incremental improvements and supports tailored offerings for different end-user environments.
Second, invest in supply chain resilience through geographic diversification of critical component sourcing, strategic partnerships with key suppliers, and enhanced inventory visibility. Scenario planning for tariff and trade volatility should be integrated into procurement governance so that pricing and contracting strategies can be executed with clarity. Third, scale post-sales services and data capabilities to offer bundled solutions that combine instrumentation with training, remote diagnostics, and performance analytics, thereby strengthening customer lock-in and enabling evidence-based value conversations with payers and health systems.
Finally, adopt commercial flexibility by offering multiple purchasing and financing options, including managed services or subscription models, to align with varying capital constraints across ambulatory centers, clinics, and hospitals. Implementing these recommendations will position organizations to capture clinical preference shifts, reduce exposure to supply disruptions, and build durable customer relationships.
Description of the mixed-method research approach integrating clinician interviews, supplier assessments, regulatory review, and scenario analysis to ensure robust insights
The research methodology underlying this analysis integrates qualitative and quantitative evidence streams to ensure a robust, triangulated perspective on industry dynamics. Primary inputs include structured interviews with clinicians, procurement leaders, and device engineering experts, which provide frontline insight into procedural preferences, reprocessing realities, and clinical workflow constraints. These interviews are complemented by supplier engagements and technical assessments that clarify manufacturing capabilities and component-level dependencies.
Secondary research encompasses regulatory guidance documents, clinical guidelines, and peer-reviewed literature on endoscopic performance and infection control. Technical validation was performed through cross-referencing product literature, device specifications, and reported outcomes from clinical studies to ensure consistency across claims and observed practice. The analytical framework emphasizes sensitivity testing and scenario analysis to explore how supply chain shocks, regulatory changes, and clinical adoption patterns could influence operational choices.
Throughout the research process, care was taken to maintain objectivity, document sources, and apply consistent criteria for evaluating evidence quality. This methodology supports actionable insights while acknowledging the complexity and regional heterogeneity that characterize the global gastroscope ecosystem.
Synthesis of strategic implications showing why integrating technical excellence with service capabilities and supply chain resilience is essential for future success
The conclusion synthesizes the principal implications for stakeholders operating in the gastroscope domain: technological innovation, procurement shifts, and trade policy considerations are collectively driving a period of strategic realignment. Manufacturers that successfully integrate high-performance imaging, service-centric commercial models, and adaptable manufacturing footprints will be better positioned to respond to evolving clinical priorities and regulatory expectations.
Moreover, the interplay between reusable and single-use paradigms, varied end-user requirements across ambulatory centers, clinics, and hospitals, and region-specific regulatory and reimbursement landscapes underscores the imperative of differentiated product and market strategies. Organizations should therefore pursue targeted investments in clinical evidence generation, post-market surveillance, and supply chain transparency to preserve customer trust and protect operational continuity.
In sum, the industry is moving toward solutions that blend clinical excellence with pragmatic service and supply capabilities. Stakeholders who act decisively to align product roadmaps, commercial structures, and operational resilience will capture disproportionate value as providers recalibrate priorities in response to both clinical needs and external policy pressures.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence assisted imaging in gastroscopes for precision diagnosis and real time pattern recognition
- 5.2. Development of single use digital gastroscopes to enhance patient safety and reduce endoscopy associated infections
- 5.3. Advancements in ultra slim transnasal gastroscope design to improve patient comfort and procedural tolerability
- 5.4. Collaboration between cloud based platforms and endoscopy software providers for remote real time gastroenterology consultation
- 5.5. Integration of narrow band imaging and chromoendoscopy features in new high resolution gastroscope models for lesion detection
- 5.6. Adoption of portable handheld gastroscope devices enabling point of care gastrointestinal diagnostics in outpatient settings
- 5.7. Emergence of robotic steering mechanisms in gastroscopes for enhanced maneuverability in minimally invasive procedures
- 5.8. Introduction of wireless capsule endoscopy systems combined with gastroscope navigation for comprehensive gastric tract visualization
- 5.9. Regulatory approval trends accelerating market entry of 3d high definition gastroscopes with digital enhancement capabilities
- 5.10. Application of augmented reality overlays during gastroscopy to assist clinicians in real time lesion identification and mapping
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Gastroscopes Market, by Product
- 8.1. Flexible
- 8.1.1. Fiberoptic
- 8.1.2. Video
- 8.2. Rigid
- 8.2.1. Reusable
- 8.2.2. Single Use
- 9. Gastroscopes Market, by Distribution Channel
- 9.1. Offline
- 9.2. Online
- 10. Gastroscopes Market, by End User
- 10.1. Ambulatory Surgical Centers
- 10.2. Clinics
- 10.3. Hospitals
- 11. Gastroscopes Market, by Application
- 11.1. Combined
- 11.2. Diagnostic
- 11.3. Therapeutic
- 12. Gastroscopes Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Gastroscopes Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Gastroscopes Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Olympus Corporation
- 15.3.2. Fujifilm Holdings Corporation
- 15.3.3. PENTAX Medical
- 15.3.4. KARL STORZ SE & Co. KG
- 15.3.5. Richard Wolf GmbH
- 15.3.6. Ambu A/S
- 15.3.7. Boston Scientific Corporation
- 15.3.8. Medtronic plc
- 15.3.9. Stryker Corporation
- 15.3.10. Smith & Nephew plc
- 15.3.11. B. Braun Melsungen AG
- 15.3.12. Cook Medical LLC
- 15.3.13. SonoScape Medical Corp.
- 15.3.14. Aohua Endoscopy Co., Ltd.
- 15.3.15. Ankon Medical Technologies Co., Ltd.
- 15.3.16. Ethicon
- 15.3.17. Mindray Bio-Medical Electronics Co., Ltd.
- 15.3.18. CONMED Corporation
- 15.3.19. Becton, Dickinson and Company
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
